MedTrace Logo

Analysis of Laboratory Markers for Severe COVID-19

NCT06460753 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 193

Last updated 2024-06-14

No results posted yet for this study

Summary

The course of coronavirus infection was often severe and required hospitalization of patients in the intensive care unit. The new SARS-Cov-2 has been poor studied, so relatively reliable markers are needed to effectively monitor patients and predict complications and outcome. Taking into account the known mechanisms of pathogenesis, the biochemical markers as ferritin, procalcitonin, C-reactive protein and D-dimer were chosen for this purpose. Patients were divided according to the degree of pulmonary infiltration. We hypothesized that the markers would correlate with dynamics, complications, and outcomes.

Conditions

  • Coronavirus Infection COVID-19

Interventions

DIAGNOSTIC_TEST

CT of the chest organs, blood biochemical parameters

Taking into account the clinical manifestations, all patients underwent chest computed tomography (CT) to diagnose COVID-19-associated pneumonia. According to the CT results, all patients were classified into one of 4 subgroups, according to the degree of pulmonary infiltration. The following biochemical parameters were selected and used to monitor dynamics: procalcitonin (PCT), C-reactive protein (CRP), D-dimer (DD), ferritin (FRT). Biochemical markers were determined daily during the stay in the intensive care unit. The duration of observation was 15 days was selected. Information was analysed retrospectively.

Sponsors & Collaborators

  • Karaganda Medical University

    lead OTHER

Principal Investigators

  • Aissulu Issabekova, MD · Karaganda Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-10
Primary Completion
2024-06-10
Completion
2024-06-10

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06460753 on ClinicalTrials.gov